ARWRHIGH SIGNALFINANCIAL10-K

ARWR dramatically improved its net loss position while revenue declined by nearly half, suggesting a major operational restructuring or significant one-time charges in the prior year.

The substantial improvement in net income performance despite lower revenue indicates either the company eliminated major one-time expenses from the prior year or achieved significant operational efficiencies. The sharp reduction in capital expenditures from $141.5M to $22.7M suggests a strategic shift in investment priorities or completion of a major build-out phase.

Comparing 2025-11-25 vs 2024-11-26View on EDGAR →
FINANCIAL ANALYSIS

ARWR's financial profile shows a dramatic turnaround with net losses improving substantially from -$599.5M to just -$1.6M, despite revenue declining nearly 49% to $16.1M. The company strengthened its balance sheet position with current assets growing 37% to $950.6M and cash increasing 28% to $184.4M, while current liabilities nearly doubled to $195.5M. The sharp 84% reduction in capital expenditures alongside higher R&D spending suggests the company is focusing resources on drug development rather than infrastructure investments.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
+99.7%
-$599.5M→-$1.6M

Net income grew 99.7% — bottom-line growth signals improving overall business health.

Current Liabilities
Balance Sheet
+89.5%
$103.2M→$195.5M

Current liabilities surged 89.5% — significant near-term obligations; verify ability to meet short-term debt.

Capital Expenditure
Cash Flow
-84%
$141.5M→$22.7M

Capex reduced 84% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Revenue
P&L
-48.6%
$31.4M→$16.1M

Revenue declined 48.6% — significant demand weakness or market share loss warrants investigation.

Current Assets
Balance Sheet
+36.7%
$695.5M→$950.6M

Current assets grew 36.7% — improving short-term liquidity or inventory/receivables build.

Cash & Equivalents
Balance Sheet
+28.5%
$143.6M→$184.4M

Cash grew 28.5% — improving liquidity position supports investment and shareholder returns.

Total Assets
Balance Sheet
+21.5%
$1.1B→$1.4B

Asset base grew 21.5% — expansion through organic growth, acquisitions, or capital deployment.

R&D Expense
P&L
+20%
$505.9M→$607.2M

R&D investment increased 20% — signals commitment to future product development, though near-term margin impact.

LANGUAGE CHANGES
NEW — 2025-11-25
PRIOR — 2024-11-26
ADDED
As of November 19, 2025, 135,809,558 shares of the issuer s Common Stock were issued and outstanding.
MARKET FOR THE REGISTRANT S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES 61 ITEM 6.
MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 62 ITEM 7A.
CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE 73 ITEM 9A.
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 74 ITEM 13.
( Arrowhead Madison ), Arrowhead Australia Pty Ltd ( Arrowhead Australia ), Arrowhead Pharmaceuticals NZ Limited ( Arrowhead New Zealand ), Arrowhead Pharmaceuticals Ireland Limited ( Arrowhead Ireland ), and Visirna Therapeutics Inc.
There are currently 18 Arrowhead discovered drug candidates in clinical trials ranging from early stage (Phase 1) to late stage (Phase 3).
The Company recently achieved a transformational milestone with its first commercial launch in 2025, when the U.S.
Food and Drug Administration ("FDA") approved REDEMPLO (plozasiran) as an adjunct to diet to reduce triglycerides in adults with Familial Chylomicronemia Syndrome ("FCS").
Additionally, phase 3 studies (SHASTA-3, SHASTA-4 and SHASTA-5) for severe hypertriglyceridemia ("sHTG") have been fully enrolled and the Company plans to file a supplemental NDA for this indication in 2026, pending successful completion of Phase 3 clinical studies.
REMOVED
As of November 20, 2024, 124,434,442 shares of the issuer s Common Stock were issued and outstanding.
M ARKET FOR THE R EGISTRANT S C OMMON E QUITY, R ELATED S TOCKHOLDER M ATTERS AND I SSUER P URCHASES OF E QUITY S ECURITIES 61 I TEM 6.
M ANAGEMENT S D ISCUSSION AND A NALYSIS OF F INANCIAL C ONDITION AND R ESULTS OF O PERATIONS 62 I TEM 7A.
C HANGES IN AND D ISAGREEMENTS WITH A CCOUNTANTS ON A CCOUNTING AND F INANCIAL D ISCLOSURE 72 I TEM 9A.
D ISCLOSURE R EGARDING F OREIGN J URISDICTIONS T HAT P REVENT I NSPECTIONS 75 PART III I TEM 10.
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 75 I TEM 13.
C ERTAIN R ELATIONSHIPS, R ELATED T RANSACTIONS AND D IRECTORS I NDEPENDENCE 75 I TEM 14.
( Arrowhead Madison ), Arrowhead Australia Pty Ltd ( Arrowhead Australia ), and Visirna Therapeutics Inc.
The Company s most advanced candidate, plozasiran, has completed a Phase 3 study in patients with familial chylomicronemia syndrome (FCS) and expects to have its first commercial launch in 2025, provided the United States Food and Drug Administration (the FDA ) accepts the New Drug Application ( NDA ) for filing and after a successful review and subsequent approval.
The Company s pipeline of 16 clinical stage investigational medicines range in development stage from Phase 1 to Phase 3.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →